Clinical trials: Buccal Cavity Cancer
Carcinoma, Ductal, Breast, Breast Cancer Female
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader (SERD) alone and in combination with palbociclib, a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, in…
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer
- Trial name
- NCT03455270
- Testing
- G1T48, Palbociclib
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Papillomavirus Infections
Effect of Oral Papilozumib on Vaginal and Intestinal Microbiota in Human Papillomavirus (HPV)-Positive Women
This open-label, single-group study evaluated the effects of a 3-month oral synbiotic dietary supplement on vaginal and intestinal microbiota in women with a positive human papillomavirus (HPV) test.
- Trial name
- NCT07755566
- Testing
- Papilozumib
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Hifas da Terra S.L.
Prostate Cancer
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.
- Trial name
- NCT01483586
- Testing
- kanglaite gelcap
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- KangLaiTe USA
Advanced Solid Neoplasms, Lymphoma Neoplasms
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659…
- Trial name
- NCT03338881
- Testing
- [14C]-TAK-659, TAK-659
- Sponsor
- Calithera Biosciences, Inc
Cervical Carcinoma Stage II, Cervical Carcinoma Stage III
Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.
The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and…
- Conditions
- Cervical Carcinoma Stage II, Cervical Carcinoma Stage III, Cervical Carcinoma Stage IV, Endometrial Adenocarcinoma Stage II
- Trial name
- NCT03540407
- Testing
- Oncoxin-Viusid®
- Where
- Cuba
- Volunteers
- 66 people
- Sponsor
- Catalysis SL
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized.
- Trial name
- NCT00778128
- Testing
- CP-4126, Gemcitabine
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 26 people
- Sponsor
- Clavis Pharma
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- NCT00234481
- Testing
- XL844
- Where
- 3 sites in United States
- Sponsor
- Exelixis
Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC)
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME.
- Conditions
- Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC), Hemimegalencephaly
- Trial name
- NCT07287202
- Testing
- SVG103
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Sovargen
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
- Trial name
- NCT02492737
- Testing
- AG881
- Where
- 6 sites in United States, France
- Volunteers
- 46 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Cancer Pain
Unique Treatment of Oncology Pain in Advanced Cancer
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to…
- Trial name
- UTOPIA-1 (NCT06533657)
- Testing
- Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- ZYUS Life Sciences Inc.
Neoplasm Malignant
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Primary Objective: To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors.
- Trial name
- NCT01836705
- Testing
- SAR302503 (TG101348), Panolosetron
- Where
- 10 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Advanced and Selected Solid Tumors
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and /or recommended phase II dose (RP2D) and schedule for the PI3K (Phosphatidylinositol 3-Kinase) inhibitor BKM120 given…
- Trial name
- NCT01155453
- Testing
- BKM120, GSK1120212
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 113 people
- Sponsor
- Novartis Pharmaceuticals
Breakthrough Pain
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a…
- Trial name
- NCT00236145
- Testing
- ACTIQ (Oral transmucosal fentanyl citrate)
- Sponsor
- Cephalon
Solid Tumor
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study to Compare Two Strengths (10 mg and 20 mg) of Senaparib Capsules in Healthy Chinese Subjects Following Oral Administration Under Fasting Condition
- Trial name
- NCT07019194
- Testing
- Senaparib capsules(20mg), Senaparib capsules(10mg)
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
CLL/SLL, Waldenstrom Macroglobulinemia
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT04775745
- Testing
- LP-168
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Newave Pharmaceutical Inc
Chronic Lymphocytic Leukemia
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
Primary objective: To determine overall response-rate, complete response (CR) or partial response (PR) Secondary objectives: To assess the safety and tolerability of ITF2357; to assess total rate of responders (complete + partial…
- Trial name
- NCT00792831
- Testing
- ITF2357
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Italfarmaco
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Carcinoma, Non-Small-Cell Lung
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or…
- Trial name
- NCT05663866
- Testing
- Dexamethasone, Montelukast, Methotrexate
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.